Ovo Labs

Ovo Labs is developing therapeutics to improve egg quality and increase IVF success rates, particularly for women in their mid-30s to early 40s. Currently, no treatments exist to enhance egg quality, which declines significantly with age—resulting in only a 13% chance of conception by age 40. Ovo Labs builds on 20 years of pioneering research in the field of female infertility in the laboratory of Prof. Melina Schuh and holds an exclusive global license covering an entire portfolio of therapeutic candidates targeting egg quality. The company raised its Seed Round in 2025 in order to take its Lead Therapeutic, EmbryoProtect1, towards clinical studies in humans